Abstract

Both in malignant and non-malignant disorders stem cell based therapies are increasingly being utilized with promising results. hematopoietic reconstitution comprises mainly of 3 types of cells bone marrow (BM), peripheral blood (PB), and umbilical cord blood (UCB). The readily available and abundant resource of stem cell is umbilical cord blood. However, the typical single UCB unit could fetch relatively low numbers of hematopoietic stem- and progenitor cells (HSPCs) and the associated delay in procuring them restrict its routine applicability. In the past decade, the clinical applications of UCBbased cell therapies have broadened with a growing number of diseases treated with hematopoietic stem cell (HSC) transplantation. The assessment of UCB unit hematopoietic stem cells (HSCs), such as CD34+ cells or CFUs (Colony forming units), may provide a more direct estimate of the hematopoietic potential of the unit than the TNC count. As interlaboratory standardization of these assays has been achieved, the selection of UCB units for banking based on quantitation of hematopoietic progenitors is currently not feasible. However, CFU assays provide the only reliable assessment of the viability of the CB unit, although great efforts have been made to develop flow cytometry methods for viability staining. Despite of extreme efforts to find strategies that would enable the ex vivo amplification of stem cells for transplantation globally, it has been proven difficult to culture the HSCs in the labs. Therefore, it is imperative to have clear understanding regarding integration of HSC self-renewal, proliferation, and differentiation, molecules participating in their regulation and clinical benefit after their modification. Attempts have been made to improve the quality of UCB units through e.g. standardization of bank procedures, of stem cell enumeration, and of the assessment of HPCs viability. Over 4000000 UCB units are currently available in international registries. However, a significant proportion of patients is still left without a suitable donor, necessitating further development of UCB banking process.

Keywords: Umbilical Cord Blood · hematopoietic stem cells

References

  1. 1.Ende M, Ende N. Hematopoietic transplantation by means of fetal (cord) blood. A new method. Va Med Mon 1972; 99: 276-80.
  2. 2.Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989; 321:1174-1178.
  3. 3.Slatter MA, Gennery AR. Umbilical cord stem cell transplantation for primary immunodeficiencies. Expert Opin Biol Ther 2006; 6: 555-65.
  4. 4.Burnouf T, Goubran HA, Chen TM, Ou KL, El-Ekiaby M, Radosevic M. Blood-derived biomaterials and platelet growth factors in regenerative medicine. Blood Rev. 2013;27:77-89.
  5. 5.Ahmed TA, Hincke MT. Mesenchymal stem cell-based tissue engineering strategies for repair of articular cartilage. Histol Histopathol 2014; 29:669-89.
  6. 6.Watt SM, Contreras M. Stem cell medicine: umbilical cord blood and its stem cell potential. Semin Fetal Neonatal Med 2005; 10: 209-20.
  7. 7.Denner L, Bodenburg Y, Zhao JG, Howe M, Cappo J, Tilton RG, et al. Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin. Cell Prolif 2007; 40: 367-80.
  8. 8.Ballen KK, Barker JN, Stewart SK, Greene MF, Lane TA. Collection and preservation of cord blood for personal use. Biol Blood Marrow Transplant 2008; , 14: 356-63.
  9. 9.Thomas ED. A history of haemopoietic cell transplantation. Br J Haematol 1999; 105: 330-339.
  10. 10.Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354; 1813-1826. Umbilical Cord Blood as a source of Hematopoietic stem cells , Rizvi MR et al 23 Review Article MAJMAAH JOURNAL HEALTH SCIENCE, 2015-vol 3, Issue 1
  11. 11.Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112, 4371-4383.
  12. 12.Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004;200:123-35.
  13. 13.Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106, 1867-1874.
  14. 14.Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, e tal. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003 ;102: 2728-2730.
  15. 15.Motabi IH, DiPersio JF. Advances in stem cell mobilization. Blood Rev 2012; 26:267-278.
  16. 16.Anasetti C, Aversa F, Brunstein CG. Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation? Biol Blood Marrow Transplant 2012; 18: S161-165.
  17. 17.Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
  18. 18.Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000; 100:157–168.
  19. 19.Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003; 21:759-806.
  20. 20.Deguchi K, Yagi H, Inada M, Yoshizaki K, Kishimoto T, Komori T. Excessive extramedullary hematopoiesis in Cbfa1-deficient mice with a congenital lack of bone marrow. Biochem Biophys Res Commun 1999; 255:352-359.
  21. 21.Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289:1501-1504.
  22. 22.Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425:841-846.
  23. 23.Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147.
  24. 24.Benvenuto F, Ferrari S, Gerdoni E, Gualandi F, Frassoni F, Pistoia V, et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007; 7:1753-60.
  25. 25.Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466:829-834.
  26. 26.Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449:1003-1007.
  27. 27.Ito M, Liu Y, Yang Z, Nguyen J, Liang F, Morris RJ, et al. Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med 2005; 12:1351-1354
  28. 28.Claudinot S, Nicolas M, Oshima H, Rochat A, Barrandon Y. Long-term renewal of hair follicles from clonogenic multipotent stem cells. Proc Natl Acad Sci USA 2005; 102:14677-14682.
  29. 29.Lois C, Garcia-Verdugo JM, Alvarez-Buylla A. Chain migration of neuronal precursors. Science 1996; 271:978-981.
  30. 30.Committee on Culture and Education, Parliamentary Assembly of the Council of Europe. Human Stem Cell Research. Hum Reprod Genet Ethics 2004; 10(2):5367.
  31. 31.Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989; 321: 1174-8.
  32. 32.Arcese W, Rocha V, Labopin M, Sanz G, Iori AP, de Lima M, et al. Eurocord-Netcord Transplant group Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 2005; 91:223-230.
  33. 33.van Heeckeren WJ, Fanning LR, Meyerson HJ, Fu P, Lazarus HM, Cooper BW, et al. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults. Br J Haematol 2007; 139:464-474.
  34. 34.Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105:1343-7.
  35. 35.Pecora AL, Stiff P, Jennis A, Goldberg S, Rosenbluth R, Price P, et al. Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood. Bone Marrow Transplant 2000; 25:797-799.
  36. 36.Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, Wall DA. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant 2001; 7:581-588 Umbilical Cord Blood as a source of Hematopoietic stem cells , Rizvi MR et al 24 Review Article MAJMAAH JOURNAL HEALTH SCIENCE, 2015-vol 3, Issue 1
  37. 37.Gang EJ, Hong SH, Jeong JA, Hwang SH, Kim SW, Yang IH, et al. In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells. Biochem Biophys Res Commun 2004; 321:102108.
  38. 38.Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007 61:219-227.
  39. 39.Zhang J, Brodie C, Li Y, Zheng X, Roberts C, Lu M, et al. Bone marrow stromal cell therapy reduces proNGF and p75 expression in mice with experimental autoimmune encephalomyelitis. J Neurol Sci 2009; 279:30-38.
  40. 40.Vercelli A, Mereuta OM, Garbossa D, Muraca G, Mareschi K, Rustichelli D, et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2008; 3:395-405.
  41. 41.Shamblott MJ, Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA 1998 ; 95: 13726-31.
  42. 42.Wobus AM, Boheler KR. Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev. 2005; 85:635-78.
  43. 43.Kerr DA, Llado J, Shamblott MJ, Maragakis NJ, Irani DN, Crawford TO, et al. Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J Neurosci 2003; 23: 5131-40.
  44. 44.Gao J, Coggeshall RE, Tarasenko YI, Wu P. Human neural stem cell-derived cholinergic neurons innervate muscle in motor neuron deficient adult rats. Neuroscience 2005; 131:257-62.
  45. 45.Kiessling AA, Anderson S. Human Embryonic Stem Cells. An Introduction to the Science and Therapeutic Potential. Massachussetts, USA: Jones and Bartlett Publishers, Inc.; 2003: 144.
  46. 46.Kelly S, Bliss TM, Shah AK, Sun GH, Ma M, Foo WC, et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci USA 2004; 101:11839-44.
  47. 47.Erdö F, Bührle C, Blunk J, Hoehn M, Xia Y, Fleischmann B, Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab 2003; 23:780-785.
  48. 48.Reubinoff B.E., Pera M.F., Fong, C-Y, Trounson A. and Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 2000; 18:399-404.
  49. 49.Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M. Insulin production by human embryonic stem cells. Diabetes 2001; 50:1691-7.
  50. 50.Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108:407-14.
  51. 51.Levenberg S, Golub JS, Amit M, Itskovitz-Eldor J, Langer R. Endothelial cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2002; 99: 4391-6.
  52. 52.Toyooka Y, Tsunekawa N, Akasu R, Noce T. Embryonic stem cells can form germ cells in vitro. Proc Natl Acad Sci USA 2003; 100:11457-62.
  53. 53.Testa G, Harris J. Ethics and synthetic gametes. Bioethics 2005; 19:146-66.
  54. 54.Chung Y, Klimanskaya I, Becker S, Marh J, Lu SJ, Johnson J, et al. Embryonic and extraembryonic stem cell lines derived from single mouse blastomeres. Nature 2006; 439:216-219.
  55. 55.Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, et al. Cordblood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med 2004; 350: 1960–69..
  56. 56.Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, et al. Transplantation of two partially HLA matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343–47.
  57. 57.Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82–89.
  58. 58.McGuckin CP, Basford C, Hanger K, Habibollah S, Forraz N. Cord blood revelations: the importance of being a first born girl, big, on time and to a young mother! Early Hum Dev. 2007; 83:733-41.
  59. 59.Felli N, Cianetti L, Pelosi E, Care A, Liu CG, Calin GA, et al. Hematopoietic differentiation: a coordinated dynamical process towards attractor stable states. BMC Syst Biol 2010; 4: 85.
  60. 60.Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. 1998. Embryonic stem cell lines derived from human blastocysts. Science, 282, 1145-7.
  61. 61.Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200: 12335.
  62. 62.Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011; 11: 268-77.
  63. 63.Sapienza C. Imprinted gene expression, transplantation medicine, and the "other" human embryonic stem Umbilical Cord Blood as a source of Hematopoietic stem cells , Rizvi MR et al 25 Review Article MAJMAAH JOURNAL HEALTH SCIENCE, 2015-vol 3, Issue 1 cell. Proc Natl Acad Sci USA 2002; 99: 10243-5.
  64. 64.Swijnenburg RJ, Schrepfer S, Govaert JA, Cao F, Ransohoff K, Sheikh AY, et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci USA 2008; 105: 12991-6.
  65. 65.Swijnenburg RJ, Tanaka M, Vogel H, Baker J, Kofidis T, Gunawan F. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005; 112: I166-72.
  66. 66.Kofidis T, Debruin JL, Tanaka M, Zwierzchoniewska M, Weissman I, Fedoseyeva E, They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. Eur J Cardiothorac Surg 2005, 28, 461-6.
  67. 67.McGuckin C, Forraz N, Baradez MO, Basford C, Dickinson AM, Navran S, et al. Embryonic-like stem cells from umbilical cord blood and potential for neural modeling. Acta Neurobiol Exp (Wars). 2006;66: 321-9.
  68. 68.Pipes BL, Tsang T, Peng SX, Fiederlein R, Graham M, Harris DT. Telomere length changes after umbilical cord blood transplant. Transfusion 2006; 46: 1038-43.
  69. 69.Slatter MA, Gennery AR. Umbilical cord stem cell transplantation for primary immunodeficiencies. Expert Opin Biol Ther 2006; 6: 555-65.
  70. 70.Kim DK, Fujiki Y, Fukushima T, Ema H, Shibuya A, et al. Comparison of hematopoietic activities of human bone marrow and umbilical cord blood CD34 positive and negative cells. Stem Cells 1999; 17: 286-94.
  71. 71.Lee MW, Moon YJ, Yang MS, Kim SK, Jang IK, Eom Y, et al. 2007. Neural differentiation of novel multipotent progenitor cells from cryopreserved human umbilical cord blood. Biochem Biophys Res Commun, 358, 63743.
  72. 72.Mcguckin C, Forraz N, Baradez MO, Basford C, Dickinson AM, Navran S, et al. Embryonic-like stem cells from umbilical cord blood and potential for neural modeling. Acta Neurobiol Exp (Wars) 2006; 66: 321-9.
  73. 73.Watt SM, Contreras M. Stem cell medicine: umbilical cord blood and its stem cell potential. Semin Fetal Neonatal Med 2005; 10: 209-20.
  74. 74.Rubinstein P, Taylor PE, Scaradavou A, Adamson JW, Migliaccio G, Emanuel D, et al. Unrelated placental blood for bone marrow reconstitution: organization of the placental blood program. Blood Cells 1994; 20:587-600.
  75. 75.Alonso JM III, Regan DM, Johnson CE, Oliver DA, Fegan R, Lasky LC, et al. A simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences. Cytotherapy 2001;3:429-33.
  76. 76.Lasky LC, Lane TA, Miller JP, Lindgren B, Patterson HA, Haley NR, et al. In utero or ex utero cord blood collection: which is better? Transfusion 2002; 42:1261-7.
  77. 77.Proctor SJ, Mounter P, Summerfield GP. Fludarabine for chronic lymphocytic leukemia. NEW England journal of medicine, "Fludarabine for chronic lymphocytic leukemia.", N ENG J MED 2001; 344: 1167.
  78. 78.Vowels MR, Lampotang PR. Cord-Blood Banking and transplantation Medical journal of Australia, "Cordblood banking and transplantation", Medical journal of Australia 1997; 166: 572-573.
  79. 79.Mugishima H, Takahashi T, Nagamura T, Asano S, Saito H. Umbilical cord blood for unrelated bone marrow replacement; Asia bank and Japan cord blood bank network update. Int J Hematol 2002;76:284-6.
  80. 80.Vanichsetakul P, Wacharaprechanont T, O-Charoen R, Seksarn P, Kupatawintu P. Umbilical cord blood transplantation in children with beta-thalassemia diseases. J Med Assoc Thai. 2004;87:S62–S67.
  81. 81.Oudshoorn M, Van Leeuwen A, vd Zanden HG, Van Rood JJ. Bone Marrow Donors Worldwide: a successful exercise in international cooperation. Bone Marrow Transplant 1994;14:3-8.
  82. 82.NETCORD: inventory and use;August 2005. At: https:// www.netcord.org/inventory.html (Accessed 29 Sept 2005).
  83. 83.Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200: 12335.
  84. 84.Ford NM, Herbert M. Stem Cells: Science, medicine, law and ethics. Strathfield, NSW: St Pauls Publications; 2003: 28.
  85. 85.Pennings G. Saviour siblings: using preimplantation genetic diagnosis for tissue typing. Int Congr Ser 2004; 1266:311-7.
  86. 86.Wernet P, Sirchia G, Garcia-Lopez J, Takahashi T, Contreras M, Gluckman E, et al. The international NETCORD organization for high quality cord blood banking and allocating [Abstract]. Blood 2001;98:388b.
  87. 87.Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
  88. 88.Lasky LC, Lane TA, Miller JP, Lindgren B, Patterson HA, Haley NR, et al. In utero or ex utero cord blood collection: which is better? Transfusion 2002;42: 1261-7.
  89. 89.US National Academy of Sciences. Guidelines for Human Embryonic Stem Cell Research. Washington D.C.: National Academy Press; 2005: 35.
  90. 90.Sylvester KG, Longaker MT. Stem cells: review and Umbilical Cord Blood as a source of Hematopoietic stem cells , Rizvi MR et al 26 Review Article MAJMAAH JOURNAL HEALTH SCIENCE, 2015-vol 3, Issue 1 update. Archives of Surgery 2004; 139:93-9.
  91. 91.Braude P, Minger SL, Warwick RM. Stem cell therapy: hope or hype? BMJ 2005; 330:1159-60.
  92. 92.Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at: http://www. cibmtr.org.
  93. 93.Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus Clin Biol 2001; 8: 146-154.
  94. 94.Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NKC, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996;88:795–802.
  95. 95.Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997;337:373–81.
  96. 96.McCann SR, Lwaler M. Mixed chimerism; detection and significant following BMT. Bone Marrow Transplant 1993; 11:91-94.
  97. 97.Solh M, Brunstein C, Morgan S, Weisdorf D. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. Biol Blood Marrow Transplant. 2011;17:710-6.
  98. 98.Thomas ED. A history of haemopoietic cell transplantation. Br J Haematol 1999; 105: 330-339.
  99. 99.Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115:1843-9.
  100. 100.Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matchedpair analysis. Blood. 2001;97:2957-61.
  101. 101.Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004; 351:2276-85.
  102. 102.Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, et al. Relapse risk after umbilical cord blood transplantation: enhanced graftversus-leukemia effect in recipients of 2 units. Blood. 2009;114:4293-9.
  103. 103.MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR, et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood. 2009; 113:2410-5.
  104. 104.Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-8.
  105. 105.Yoo KH, Lee SH, Kim HJ, Sung KW, Jung HL, Cho EJ, et al. The impact of post-thaw colony-forming unitsgranulocyte/macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant 2007; 39:515-21.
  106. 106.Thomson BG, Robertson KA, Gowan D, Heilman D, Broxmeyer HE, Emanuel D, Kotylo P, Brahmi Z, Smith FO. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood. 2000 Oct 15;96(8):2703-11.
  107. 107.American Association of Blood Banks. Standards for hematopoietic progenitor cell services. 2nd ed. Bethesda (MD): American Association of Blood Banks; 2000. Umbilical Cord Blood as a source of Hematopoietic stem cells , Rizvi MR et al 27
Majmaah Journal of Health Sciences · eISSN 1658-8223 · Majmaah University · open access